Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Loxiglumide (CR-1505) is an antagonist of cholecystokinin (CCK-1) receptor.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
無料サンプル 1 mg | |||||
5 mg | 在庫あり | ¥ 8,000 | |||
10 mg | 在庫あり | ¥ 13,000 | |||
25 mg | 在庫あり | ¥ 27,500 | |||
50 mg | 在庫あり | ¥ 54,500 | |||
100 mg | 在庫あり | ¥ 96,000 | |||
500 mg | 在庫あり | ¥ 217,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 8,000 |
説明 | Loxiglumide (CR-1505) is an antagonist of cholecystokinin (CCK-1) receptor. |
キナーゼ試験 | Kinase binding assays: For optimization of Axl/TAM receptor inhibitors, an Axl binding assay is established (HTRF method; Kinase tracer 236). This assay is based on the binding and displacement of the Alexa Fluor 647-labelled Kinase tracer 236 to each glutathione S-transferase (GST)-tagged kinase used in the binding assay. Binding of the tracer to the kinase was detected by using europium (Eu)-labelled anti-GST antibodies. Simultaneous binding of both the fluorescent tracer and the Eu-labelled antibodies to the GST-tagged kinase generates a fluorescence resonance energy transfer (FRET) signal. Binding of inhibitor to the kinase competes for binding with the tracer, resulting in a loss of the FRET signal. For the assay, the compound is diluted in 20?mM HEPES, pH?8.0, 1?mM DTT, 10?mM MgCl2 and 0.01% Brij35. Then, the kinase of interest (5?nM final concentration), fluorescent tracer (15?nM final concentration) and LanthaScreen Eu-anti-GST antibody (2?nM final concentration) are mixed with the respective compound dilutions (from 5?nM to 10?μM) and incubated for 1?h. The FRET signal is quantified using an EnVision Multilabellreader 2104. |
別名 | CR-1505 |
分子量 | 461.38 |
分子式 | C21H30Cl2N2O5 |
CAS No. | 107097-80-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4.61 mg/mL (10 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Loxiglumide 107097-80-3 GPCR/G Protein cholecystokinin CR-1505 CCK Receptor Inhibitor CR1505 CR 1505 inhibit Cholecystokinin Receptor inhibitor